(Q40174813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Caraco Y

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Blotnick S

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

12 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

460-470

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Managing oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Why do patients with atrial fibrillation not receive warfarin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Risk factors for intracranial hemorrhage in outpatients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Major bleeding caused by warfarin in a genetically susceptible patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Increased sensitivity to warfarin after heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Management and dosing of warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100316

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851566%20AND%20SRC:MED&resulttype=core&format=json

release_k5cykbx4lvaotnv6ro4gvbjioa

7 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k5cykbx4lvaotnv6ro4gvbjioa

24 November 2022

mapped directly with Wikidata item

1 reference